Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Events

Stock Quote

Change
Volume
52 Week High
52 Week Low

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12
TUCSON, Ariz. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the third quarter ended September 30, 2019 after the market close on
Toggle Summary HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on Breast Cancer Molecular Diagnostics on October 29
TUCSON, Ariz. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) , a diagnostic company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Tuesday, October 29 th in New York City .
Toggle Summary HTG Announces the Launch of its New Autoimmune Profiling Assay
TUCSON, Ariz. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it will begin taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is expected to be
Toggle Summary HTG Molecular Diagnostics, Inc. Provides Update Regarding Companion Diagnostic Development Programs
TUCSON, Ariz. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today provided an update regarding its ongoing efforts related to the development, manufacture and commercialization of
Toggle Summary HTG Molecular to Present Corporate Overview at the Cantor 2019 Global Healthcare Conference
TUCSON, Ariz. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that John Lubniewski , President and CEO, will present a corporate overview at the Cantor 2019 Global

Stock Chart

SEC Filings

Filing date Description

Simplified registration form

An amendment to the SC 13G filing

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities